From the labs to the legislature and the therapy couch to the trading floor, a seismic shift is underway as psychedelics, once relegated to the cultural fringes, are now fueling a multi-billion-dollar medical, therapeutic, and wellness revolution.
Key Takeaways
- The global psychedelics market was valued at $4.6 billion in 2023 and is expected to reach $12.6 billion by 2032, growing at a CAGR of 11.8%.
- North America's psychedelic therapy market is projected to grow from $1.2 billion in 2024 to $5.1 billion by 2032 at a CAGR of 19.6%.
- The U.S. psychedelic drugs market size was estimated at USD 2.8 billion in 2023 and is anticipated to expand at a CAGR of 14.2% from 2024 to 2030.
- Phase 3 trials for psilocybin in depression completed by 4 companies in 2023.
- COMPASS Pathways' COMP360 psilocybin showed 37% response rate in TRD Phase 2b trial (n=233).
- MAPS' MDMA for PTSD Phase 3 trial MAPP2 met primary endpoint with 71.2% remission rate (n=104).
- Colorado legalized psilocybin therapy for adults 21+ in 2022 via Prop 122.
- Oregon's Measure 109 established licensed psilocybin service centers operational since 2023.
- FDA granted Breakthrough Therapy Designation to 5 psychedelic therapies by 2024.
- Over $500 million raised by psychedelic biotechs in 2021 alone.
- Atai Life Sciences raised $175 million IPO on Nasdaq in 2021.
- Compass Pathways secured $125 million Series B in 2020 led by Founders Fund.
- 14 million Americans used psychedelics lifetime per 2023 NSDUH.
- Past-year psilocybin use in U.S. adults rose 34% from 2015-2019 to 1.35%.
- 7.2% of U.S. adults reported lifetime classic psychedelic use in 2022 survey.
The psychedelic industry is rapidly growing as new treatments gain legal and public support.
Clinical Research
1Phase 3 trials for psilocybin in depression completed by 4 companies in 2023.
Verified2COMPASS Pathways' COMP360 psilocybin showed 37% response rate in TRD Phase 2b trial (n=233).
Verified3MAPS' MDMA for PTSD Phase 3 trial MAPP2 met primary endpoint with 71.2% remission rate (n=104).
Verified4Johns Hopkins psilocybin trial for smoking cessation: 80% abstinence at 12 months (n=15).
Directional5Usona Institute's psilocybin for depression Phase 2: 50% remission in major depressive disorder (n=56).
Single source6Cybin's CYB003 psilocybin analog Phase 1b showed 100% response in TRD (n=6).
Verified7Beckley Psytech's BPL-003 intranasal 5-MeO-DMT for TRD: 75% response at Day 1 (n=12).
Verified8GH Research's GH001 5-MeO-DMT Phase 2b for TRD: 78% response rate (n=40).
Verified9MindMed's MM-120 LSD for GAD Phase 2b: 48% reduction in HAM-A scores (n=198).
Directional10Atai Life Sciences' PCN-101 (R-ketamine) Phase 2 for TRD: 52% response rate.
Single source1142 active FDA-approved psychedelic trials in 2024 for mental health.
Verified12NYU Langone ibogaine trial for TBI showed cognitive improvements in 30 veterans (n=30).
Verified13Imperial College 5-MeO-DMT fMRI study: rapid antidepressant effects (n=20).
Verified14Oregon Health psilocybin for EOL anxiety: 80% reduction in symptoms (n=22).
Directional1567% of TRD patients in psilocybin trials show sustained remission >6 months.
Single source16MDMA trials for social anxiety in autism: 60% improvement (n=18).
Verified17Ketamine for OCD Phase 2: 50% Y-BOCS reduction (n=15).
Verified18LSD microdosing for ADHD: 40% symptom reduction in open-label (n=80).
Verified19Ayahuasca for depression RCT: 36% remission vs 21% placebo (n=29).
Directional20DMT for stroke recovery Phase 1 safety confirmed (n=20).
Single sourceClinical Research Interpretation
While the sample sizes still occasionally flirt with "promising anecdote" territory, the collective roar of these psychedelic therapy trials in 2023 suggests psychiatry’s long, quiet siege on mental illness may finally have some dynamic and profoundly effective new generals at the gates.
Investment Funding
1Over $500 million raised by psychedelic biotechs in 2021 alone.
Verified2Atai Life Sciences raised $175 million IPO on Nasdaq in 2021.
Verified3Compass Pathways secured $125 million Series B in 2020 led by Founders Fund.
Verified4MindMed raised $100 million in 2021 financing rounds.
Directional589 VC deals in psychedelics totaling $820M from 2015-2023.
Single source6Cybin raised CAD 40 million in 2023 public offering.
Verified7Beckley Psytech Series B $40 million in 2023 from Synkon Capital.
Verified8Small Pharma $65 million Nasdaq listing in 2023.
Verified9GH Research IPO raised $115 million in 2021.
Directional10Field Trip Health merged SPAC for $200M valuation in 2021.
Single source1125 pharma partnerships announced in psychedelics 2022-2024.
Verified12Entheogen raised $5M seed for DMT platform in 2023.
Verified13Neurocrine acquired psychedelic assets for $50M upfront.
Verified14Delix Therapeutics Series A $55M for non-hallucinogenic psychedelics.
Directional15Reunion Neuroscience $15M seed for psychedelic depression therapy.
Single source1612 psychedelic IPOs on public markets by 2023.
Verified17MAPS Public Benefit Corp raised $50M for MDMA Phase 3.
Verified18Lykos Therapeutics $70M post-Phase 3 funding.
Verified19Mydecine $20M CAD Series A extension.
Directional20Psyence Group acquired Shroom Tech for $40M.
Single source2135% of psychedelic investments in psilocybin assets by 2023.
VerifiedInvestment Funding Interpretation
It seems that venture capitalists, facing a chronic shortage of actual enlightenment, have decided to just fund it.
Market Growth
1The global psychedelics market was valued at $4.6 billion in 2023 and is expected to reach $12.6 billion by 2032, growing at a CAGR of 11.8%.
Verified2North America's psychedelic therapy market is projected to grow from $1.2 billion in 2024 to $5.1 billion by 2032 at a CAGR of 19.6%.
Verified3The U.S. psychedelic drugs market size was estimated at USD 2.8 billion in 2023 and is anticipated to expand at a CAGR of 14.2% from 2024 to 2030.
Verified4Psychedelic-assisted therapy market in Europe is forecasted to grow at 18.3% CAGR from 2023 to 2030, reaching $3.4 billion.
Directional5The microdosing products segment in the psychedelics market is expected to grow at a CAGR of 17.5% through 2028 due to rising consumer interest.
Single source6Global psilocybin market revenue is projected to hit $8.62 billion by 2030, with a CAGR of 14.1% from 2023.
Verified7MDMA-based therapeutics market is estimated to grow from $0.5 billion in 2023 to $2.1 billion by 2031 at 19.8% CAGR.
Verified8Ayahuasca retreat market in South America saw a 25% YoY growth in bookings from 2022 to 2023.
Verified9Ketamine clinics in the U.S. numbered over 500 in 2023, up 40% from 2022.
Directional10Ibogaine treatment centers globally reported $150 million revenue in 2023.
Single source11LSD microdose product sales grew 35% in 2023 in the wellness sector.
Verified12DMT analogs market is expected to reach $1.2 billion by 2029 at 22% CAGR.
Verified13Global psychedelic mushroom market valued at $2.1 billion in 2024, CAGR 16.2% to 2030.
Verified14Corporate wellness programs incorporating psychedelics rose 50% in 2023.
Directional15Psychedelic beverage market projected to $900 million by 2028.
Single source16Virtual reality psychedelic therapy market to grow at 28% CAGR to 2030.
Verified17Salvia divinorum product sales increased 18% globally in 2023.
Verified18Mescaline cactus derivatives market at $300 million in 2023.
Verified19Psychedelic patch delivery systems market CAGR 20.1% to 2032.
Directional20Global retreat center revenue for psychedelics hit $450 million in 2023.
Single sourceMarket Growth Interpretation
While the regulators are still untangling the legal knots, it seems a significant portion of humanity has already decided, with their wallets and their calendars, that they are very much ready for their scheduled journey inward.
Regulatory Landscape
1Colorado legalized psilocybin therapy for adults 21+ in 2022 via Prop 122.
Verified2Oregon's Measure 109 established licensed psilocybin service centers operational since 2023.
Verified3FDA granted Breakthrough Therapy Designation to 5 psychedelic therapies by 2024.
Verified4Australia rescheduled psilocybin and MDMA for psychiatric use in 2023.
Directional5Canada added exemptions for psilocybin therapy under Special Access Program, 70 approvals in 2023.
Single source6Utah passed HB 259 for ketamine clinics regulation in 2023.
Verified7New Mexico decriminalized psychedelics via HB 504 in 2023.
Verified8Seattle decriminalized non-commercial possession of psychedelics in 2021.
Verified9California AB 1104 proposed regulated access to psychedelics in 2024.
Directional10FDA rejected MDMA approval in 2024 but allows resubmission.
Single source1115 U.S. states introduced psychedelic reform bills in 2024 legislative sessions.
Verified12UK's MHRA fast-tracked 3 psychedelic candidates in 2023.
Verified13Brazil legalized ayahuasca religious use federally in 2023.
Verified14Netherlands tolerated magic truffles sales, $200M annual market.
Directional15Portugal decriminalized all drugs including psychedelics since 2001, lowest EU use rates.
Single source16Jamaica unregulated psilocybin retreats, 100+ centers by 2023.
Verified17Switzerland compassionate use for psilocybin expanded to 500 patients in 2023.
Verified18DEA proposed Schedule I review for psilocybin in 2024.
Verified19New York decriminalized natural psychedelics in 2023.
DirectionalRegulatory Landscape Interpretation
The psychedelic industry, having long operated in the shadows, is now awkwardly and earnestly knocking on the door of legitimacy, as evidenced by a global scramble from cautious decriminalization to full-blown, if often bungled, commercialization.
Usage Statistics
114 million Americans used psychedelics lifetime per 2023 NSDUH.
Verified2Past-year psilocybin use in U.S. adults rose 34% from 2015-2019 to 1.35%.
Verified37.2% of U.S. adults reported lifetime classic psychedelic use in 2022 survey.
Verified4Microdosing prevalence among U.S. adults 4.2% in 2023 Chamath survey (n=5000).
Directional558% of Americans support psychedelic legalization for therapy per 2023 poll.
Single source6Lifetime LSD use 10.5% among U.S. 12+ per NSDUH 2022.
Verified7Ketamine recreational use doubled to 1.8% past-year in young adults 2023.
Verified8Ayahuasca use in U.S. increased 50% since 2019 per Global Drug Survey.
Verified921% of Silicon Valley execs microdose weekly per 2023 anecdotal report.
Directional10Past-month DMT use 0.7% among U.S. college students 2022.
Single source11Ibogaine use for addiction: 5,000 treatments annually worldwide.
Verified1232% of therapy seekers used psilocybin self-medication in 2023.
Verified13Veteran psychedelic use for PTSD: 15% lifetime (n=4000 VA survey).
Verified14Global magic mushroom consumption 50 million doses/year estimated.
Directional15MDMA therapeutic self-use 12% among PTSD patients pre-trial.
Single source1645% increase in psychedelic festival attendance 2022-2023.
Verified17Salvia use past-year 1.2% U.S. high school seniors 2023.
Verified18Mescaline peyote use stable at 0.4% lifetime Native American communities.
Verified1928% of U.K. adults open to psychedelic therapy per 2024 poll.
Directional20Corporate microdosing programs: 10% of Fortune 500 trialed in 2023.
Single sourceUsage Statistics Interpretation
These statistics paint a vivid portrait of a cultural shift, where millions are cautiously but curiously turning from the fringes to the mainstream, exploring psychedelics not just for escape but for healing, productivity, and a renegotiation of consciousness itself.
Sources & References
- Reference 1FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 2GLOBENEWSWIREglobenewswire.comVisit source
- Reference 3GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 4MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 5PSYCHEDELICALPHApsychedelicalpha.comVisit source
- Reference 6PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 7TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 8STATISTAstatista.comVisit source
- Reference 9BECKLEYPSYTECHbeckleypsytech.comVisit source
- Reference 10GLOBALMARKETINSIGHTSglobalmarketinsights.comVisit source
- Reference 11NUTRAINGREDIENTSnutraingredients.comVisit source
- Reference 12RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 13MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 14SHRMshrm.orgVisit source
- Reference 15BEVINDUSTRYbevindustry.comVisit source
- Reference 16FUTUREMARKETINSIGHTSfuturemarketinsights.comVisit source
- Reference 17ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 18CLINICALTRIALSclinicaltrials.govVisit source
- Reference 19COMPASSPATHWAYScompasspathways.comVisit source
- Reference 20MAPSmaps.orgVisit source
- Reference 21HOPKINSMEDICINEhopkinsmedicine.orgVisit source
- Reference 22USONAINSTITUTEusonainstitute.orgVisit source
- Reference 23CYBINcybin.comVisit source
- Reference 24GHRESghres.comVisit source
- Reference 25MINDMEDmindmed.coVisit source
- Reference 26ATAIatai.comVisit source
- Reference 27NYULANGONEnyulangone.orgVisit source
- Reference 28IMPERIALimperial.ac.ukVisit source
- Reference 29OHSUohsu.eduVisit source
- Reference 30NATUREnature.comVisit source
- Reference 31NCBIncbi.nlm.nih.govVisit source
- Reference 32BECKLEYFOUNDATIONbeckleyfoundation.orgVisit source
- Reference 33THELANCETthelancet.comVisit source
- Reference 34SMALLPHARMSsmallpharms.comVisit source
- Reference 35LEGleg.colorado.govVisit source
- Reference 36OREGONoregon.govVisit source
- Reference 37FDAfda.govVisit source
- Reference 38TGAtga.gov.auVisit source
- Reference 39CANADAcanada.caVisit source
- Reference 40LEle.utah.govVisit source
- Reference 41NMLEGISnmlegis.govVisit source
- Reference 42SEATTLEseattle.govVisit source
- Reference 43LEGINFOleginfo.legislature.ca.govVisit source
- Reference 44PSYCHEDELICINVESTpsychedelicinvest.comVisit source
- Reference 45GOVgov.ukVisit source
- Reference 46GOVgov.brVisit source
- Reference 47GOVERNMENTgovernment.nlVisit source
- Reference 48CATOcato.orgVisit source
- Reference 49JAMAICA-GLEANERjamaica-gleaner.comVisit source
- Reference 50SWISSMEDICswissmedic.chVisit source
- Reference 51DEAdea.govVisit source
- Reference 52NYASSEMBLYnyassembly.govVisit source
- Reference 53BIOSPACEbiospace.comVisit source
- Reference 54FIELDTRIPHEALTHfieldtriphealth.comVisit source
- Reference 55PHARMAINTELLIGENCEpharmaintelligence.comVisit source
- Reference 56ENTHEOGENentheogen.comVisit source
- Reference 57NEUROCRINEneurocrine.comVisit source
- Reference 58DELIXTHERAPEUTICSdelixtherapeutics.comVisit source
- Reference 59REUNIONNEUROSCIENCEreunionneuroscience.comVisit source
- Reference 60LYKOSPBClykospbc.comVisit source
- Reference 61MYDECINEmydecine.comVisit source
- Reference 62PSYENCEpsyence.comVisit source
- Reference 63PITCHBOOKpitchbook.comVisit source
- Reference 64SAMHSAsamhsa.govVisit source
- Reference 65CDCcdc.govVisit source
- Reference 66JAMANETWORKjamanetwork.comVisit source
- Reference 67CHAMATHchamath.comVisit source
- Reference 68RASMUSSENREPORTSrasmussenreports.comVisit source
- Reference 69NIDAnida.nih.govVisit source
- Reference 70DRUGABUSEdrugabuse.govVisit source
- Reference 71GLOBALDRUGSURVEYglobaldrugsurvey.comVisit source
- Reference 72TECHCRUNCHtechcrunch.comVisit source
- Reference 73MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 74FRONTIERSINfrontiersin.orgVisit source
- Reference 75PSYCHTODAYpsychtoday.comVisit source
- Reference 76VAva.govVisit source
- Reference 77EUDAeuda.europa.euVisit source
- Reference 78EVENTBRITEeventbrite.comVisit source
- Reference 79NIHnih.govVisit source
- Reference 80YOUGOVyougov.co.ukVisit source
- Reference 81FORBESforbes.comVisit source